ClinicalTrials.gg
RecruitingNCT07377006Updated Sep 25, 2026

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

An interventional study of Behavioral Intervention and Biospecimen Collection in Prostate Carcinoma, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Sep 25, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center — 22 open to participants now, 40 under way, 3 of them phase 3. Prostatic Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
27th of 106
108 · median 41
Started
2026
with 3 others
No phase
25 of 124
8 open now
Primary completion
2030-05
later than 37 of 39 live
Registered
122nd of 124
by date

Among the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, this one is the 27th largest by planned enrollment of the 106 interventional ones that give a count, is one of 4 that started in 2026, is one of 25 with no phase, reaches primary completion later than 37 of the 39 other live ones, and was the 122nd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies in Prostatic Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Read the detailed description

PRIMARY OBJECTIVES:

I. Identify patient, provider, and health system factors contributing to the completion of recommended germline testing for men with prostate cancer.

II. Develop a decision support tool for patients tailored to the cultural and socioeconomic context of the local community.

III. Conduct a pilot intervention trial to evaluate a point-of-care decision support tool in a public safety net hospital in Harris County, Texas.

SECONDARY OBJECTIVES:

I. Assess the feasibility of point-of-care decision support tool in a public safety net hospital in Harris County, Texas.

II. Assess the change in completion of germline genetic testing with utilization of the decision support tool.

OUTLINE: At each stage of the proposed research, patients are recruited to 1 of 3 groups. Groups 1 and 2 are observational and group 3 is a pilot interventional trial.

GROUP 1: Patients complete a qualitative interview that informs the development of the decision support tool.

GROUP 2: Patients view the draft of the decision support tool and complete cognitive interviews for the refinement of the decision support tool on study.

GROUP 3: Patients view the decision support tool that provides culturally tailored information about genetic testing and the collection process. Patients may then provide a blood sample for standard of care genetic testing and may additionally meet with a genetics counselor for additional information prior to testing. Patients with a positive germline genetic mutation will discuss results with a genetics counselor.

03

Conditions studied

  • Prostate Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital
  • Were recommended for germline genetic testing by their oncology provider
  • Can provide
  • Can communicate in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Other
    Group 1 (Qualitative interview)

    Patients complete a qualitative interview that informs the development of the decision support tool.

    Other: Electronic Health Record Review · Other: Interview

  • Other
    Group 2 (Draft decision support tool, cognitive interview)

    Patients view the draft of the decision support tool and complete cognitive interviews for the refinement of the decision support tool on study.

    Behavioral: Behavioral Intervention · Other: Interview

  • Experimental
    Group 3 (Decision tool)

    Patients view the decision support tool that provides culturally tailored information about genetic testing and the collection process. Patients may then provide a blood sample for standard of care genetic testing and may additionally meet with a genetics counselor for additional information prior to testing. Patients with a positive germline genetic mutation will discuss results with a genetics counselor.

    Behavioral: Behavioral Intervention · Procedure: Biospecimen Collection · Other: Genetic Counseling · Other: Genetic Testing · Other: Survey Administration

Interventions

  • BehavioralBehavioral Intervention

    View decision support tool

    Also known as: Behavior Conditioning Therapy, Behavior Modification, Behavior or Life Style Modifications, Behavior Therapy, Behavioral, Behavioral Interventions, Behavioral Modification, Behavioral Therapy, Behavioral Treatment, Behavioral Treatments

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • OtherElectronic Health Record Review

    Ancillary studies

  • OtherGenetic Counseling

    Meet with genetic counselor

  • OtherGenetic Testing

    Undergo standard of care genetic testing

    Also known as: Genetic Analysis, Genetic Examination, Genetic Test

  • OtherInterview

    Complete qualitative interview

  • OtherInterview

    Complete cognitive interview

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Safety and Adverse Events (AEs)

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2030, 51 months after the start.

Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 51 months is above that.

Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Feb 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Jan 29, 2026
StartActual
Feb 2, 2026was Oct 2026
Primary completionEst.
May 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 25, 2026
Sites
M D Anderson Cancer Center is now Recruiting
Sep 25, 2026
Start date
Oct 1, 2026→Feb 2, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Not yet recruiting→Recruiting
    M D Anderson Cancer Center is now Recruiting
    Start date Oct 1, 2026→Feb 2, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07377006
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Feb 2, 2026
Primary completion
May 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Sep 25, 2026

Study contacts

Debanjan Pain
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion